Cybin (NYSEAMERICAN:CYBN) Shares Up 7.5%

Shares of Cybin Inc. (NYSEAMERICAN:CYBN) were up 7.5% on Friday . The stock traded as high as $9.20 and last traded at $9.20. Approximately 47,540 shares changed hands during trading, a decline of 64% from the average daily volume of 130,696 shares. The stock had previously closed at $8.56.

Cybin Stock Up 9.8 %

The company has a market cap of $3.86 billion, a PE ratio of -44.52 and a beta of 0.50.

Cybin (NYSEAMERICAN:CYBN) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. Equities analysts expect that Cybin Inc. will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Cybin

A hedge fund recently bought a new stake in Cybin stock. Rathbones Group PLC purchased a new stake in Cybin Inc. (NYSEAMERICAN:CYBN) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 65,381 shares of the company’s stock, valued at approximately $26,000. 17.94% of the stock is owned by institutional investors and hedge funds.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.